Idogen Investor Relations Material
Latest events
Q1 2023
9 May, 2023
Q4 2022
24 Feb, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Idogen
Access all reports
Idogen AB (publ) is a biotechnology company, which develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs and the body's own cells or tissues. The company's advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IDOGEN
Country
🇸🇪 Sweden